Ionis Pharmaceuticals, Inc. Common Stock
IONSIonis Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics. Founded in 1989, the company focuses on using antisense technology to develop medicines for various diseases, including neurological, rare, and severe conditions. Ionis is known for its innovative approach to addressing unmet medical needs through gene-silencing strategies.
Company News
The global amyloidosis therapeutics market is experiencing strong growth, valued at $2.95 billion in 2024 and expected to reach $6.37 billion by 2033 with a 9.20% CAGR. Growth is driven by accelerating ATTR cardiomyopathy diagnosis through imaging technologies, rapid uptake of disease-modifying therapies in North America, and expanded reimburseme...
GSK and Ionis Pharmaceuticals announced positive Phase 3 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B. The B-Well 1 and B-Well 2 studies, involving over 1,800 patients, met their primary endpoint with statistically significant functional cure rates. If approved, bepirovirsen could become the...
Biogen has acquired Alcyone Therapeutics, a clinical-stage biotechnology company, to enhance its CNS therapy delivery solutions through the ThecaFlex DRxâ„¢ drug delivery system, which aims to provide an alternative to repeat lumbar punctures for neurologic disorder treatments.
Ionis Pharmaceuticals reported positive results from a clinical trial of zilganersen for Alexander disease, showing statistically significant stabilization of gait speed and the first evidence of disease modification in this rare neurological condition.
Antisense oligonucleotide (ASO) therapeutics are emerging as a promising treatment approach for rare genetic and neuromuscular disorders, with over 70 pharmaceutical companies actively developing 90+ pipeline therapeutics targeting specific genetic mechanisms.
